Lv1
78 积分 2024-10-11 加入
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study
1个月前
已完结
[Expert consensus on conversion therapy of biliary tract cancer (2025)]
2个月前
已完结
Neoadjuvant therapy in gall bladder cancer improves resectability and survival: a prospective study
2个月前
已关闭
Anti-PD-L1 biomimetic nanobubbles for ultrasound-triggered reprogramming of cold hepatocellular carcinoma for immunotherapy
2个月前
已完结
Multifaceted mechanisms and precision strategies to overcome therapeutic resistance in gallbladder cancer
2个月前
已关闭
Neoadjuvant therapy in gall bladder cancer improves resectability and survival: a prospective study
2个月前
已关闭
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial
4个月前
已完结
Are Biopsy Specimens Effective for Evaluating HER2 Expression in Extrahepatic Bile Duct and Gallbladder Cancer?
4个月前
已完结
Age-standardized mortality-to-incidence ratio for gallbladder cancer in the world
4个月前
已关闭
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial
5个月前
已完结
Lead-Free CsMnCl3 Nanoparticles with Tunable Dual Fluorescence for Light-Emitting Applications
皖公网安备34019202002308
